Beam Therapeutics (BEAM) Cash from Financing Activities (2019 - 2025)
Historic Cash from Financing Activities for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $1.7 million.
- Beam Therapeutics' Cash from Financing Activities rose 3272.58% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $479.6 million, marking a year-over-year increase of 116195.76%. This contributed to the annual value of $7.7 million for FY2024, which is 9720.16% down from last year.
- Latest data reveals that Beam Therapeutics reported Cash from Financing Activities of $1.7 million as of Q3 2025, which was up 3272.58% from $1.1 million recorded in Q2 2025.
- Beam Therapeutics' 5-year Cash from Financing Activities high stood at $473.4 million for Q1 2025, and its period low was $133000.0 during Q2 2024.
- For the 5-year period, Beam Therapeutics' Cash from Financing Activities averaged around $85.7 million, with its median value being $32.0 million (2022).
- In the last 5 years, Beam Therapeutics' Cash from Financing Activities skyrocketed by 34126808.51% in 2021 and then plummeted by 9987.63% in 2024.
- Quarter analysis of 5 years shows Beam Therapeutics' Cash from Financing Activities stood at $21.5 million in 2021, then surged by 48.6% to $32.0 million in 2022, then grew by 5.31% to $33.7 million in 2023, then plummeted by 89.78% to $3.4 million in 2024, then plummeted by 51.36% to $1.7 million in 2025.
- Its Cash from Financing Activities stands at $1.7 million for Q3 2025, versus $1.1 million for Q2 2025 and $473.4 million for Q1 2025.